$ATXI
Avenue Therapeutics Inc

2021 Q4 Form 10-Q Financial Statement

#000141057821000225 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $524.0K $594.0K $570.0K
YoY Change 0.77% 4.21% -8.06%
% of Gross Profit
Research & Development $390.0K $278.0K $466.0K
YoY Change -18.75% -40.34% -72.75%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $914.0K $278.0K $466.0K
YoY Change -8.6% -40.34% -79.91%
Operating Profit -$872.0K -$1.037M
YoY Change -15.91%
Interest Expense $1.000K $1.000K $10.00K
YoY Change -90.0% -90.0% -87.5%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$913.0K -$871.0K -$1.030M
YoY Change -7.78% -15.44% -54.02%
Income Tax
% Of Pretax Income
Net Earnings -$913.0K -$871.0K -$1.028M
YoY Change -7.78% -15.27% -54.11%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.06
Diluted Earnings Per Share -$50.03K -$0.05 -$0.06
COMMON SHARES
Basic Shares Outstanding 18.70M 16.63M 16.52M
Diluted Shares Outstanding 16.63M 16.52M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.763M $585.0K $4.330M
YoY Change 20.22% -86.49% -68.49%
Cash & Equivalents $3.763M $600.0K $4.325M
Short-Term Investments
Other Short-Term Assets $107.0K $29.00K $30.00K
YoY Change -2.73% -3.33% -78.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.960M $688.0K $4.350M
YoY Change 22.03% -84.18% -68.66%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.960M $688.0K $4.350M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $3.960M $688.0K $4.350M
YoY Change 22.03% -84.18% -68.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $304.0K $202.0K $400.0K
YoY Change 112.59% -49.5% -50.62%
Accrued Expenses $205.0K $646.0K $720.0K
YoY Change -72.3% -10.28% -35.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $509.0K $848.0K $1.120M
YoY Change -42.55% -24.29% -41.67%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $509.0K $848.0K $1.120M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $509.0K $848.0K $1.120M
YoY Change -42.55% -24.29% -41.67%
SHAREHOLDERS EQUITY
Retained Earnings -$77.00M -$76.10M
YoY Change 5.09%
Common Stock $80.45M $75.93M
YoY Change 6.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.451M -$160.0K $3.234M
YoY Change
Total Liabilities & Shareholders Equity $3.960M $688.0K $4.350M
YoY Change 22.03% -84.18% -68.66%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$913.0K -$871.0K -$1.028M
YoY Change -7.78% -15.27% -54.11%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.203M -$536.0K -$930.0K
YoY Change 1.09% -42.37% -45.61%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.381M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.203M -536.0K -930.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 4.381M 0.000
Net Change In Cash 3.178M -536.0K -930.0K
YoY Change -367.06% -42.37% -45.61%
FREE CASH FLOW
Cash From Operating Activities -$1.203M -$536.0K -$930.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16627427
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16519464
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16580283
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16489701
dei Entity Central Index Key
EntityCentralIndexKey
0001644963
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16747803
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16793693
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38114
dei Entity Registrant Name
EntityRegistrantName
AVENUE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
dei Entity Address Address Line1
EntityAddressAddressLine1
1140 Avenue of the Americas, Floor 9
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
652-4500
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ATXI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18700480
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
585000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3132000
CY2021Q3 us-gaap Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
74000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
113000
CY2021Q3 us-gaap Assets
Assets
688000
CY2020Q4 us-gaap Assets
Assets
3245000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
672000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
857000
CY2021Q3 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
176000
CY2020Q4 atxi Accounts Payable And Accrued Expenses Related Party Current
AccountsPayableAndAccruedExpensesRelatedPartyCurrent
29000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
848000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
886000
CY2021Q3 us-gaap Liabilities
Liabilities
848000
CY2020Q4 us-gaap Liabilities
Liabilities
886000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16793693
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16747803
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
75924000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
75625000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76086000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73268000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-160000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2359000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
688000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3245000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
278000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
466000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
864000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2382000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
594000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
571000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1960000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1832000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-872000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1037000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2824000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4214000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
us-gaap Investment Income Interest
InvestmentIncomeInterest
56000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-871000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1028000
us-gaap Net Income Loss
NetIncomeLoss
-2818000
us-gaap Net Income Loss
NetIncomeLoss
-4158000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16627427
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16519464
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16580283
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16489701
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
642000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
69000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-871000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-160000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2359000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
299000
atxi Share Issued During Period Value Warrants Exercised
ShareIssuedDuringPeriodValueWarrantsExercised
0
us-gaap Net Income Loss
NetIncomeLoss
-2818000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-160000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
4101000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
161000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1028000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3234000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6800000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
592000
us-gaap Net Income Loss
NetIncomeLoss
-4158000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
3234000
us-gaap Profit Loss
ProfitLoss
-2818000
us-gaap Profit Loss
ProfitLoss
-4158000
us-gaap Share Based Compensation
ShareBasedCompensation
299000
us-gaap Share Based Compensation
ShareBasedCompensation
592000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-74000
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-84000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-143000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-185000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
147000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
17000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2547000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3420000
atxi Milestone Payment For Research And Development Licenses
MilestonePaymentForResearchAndDevelopmentLicenses
0
atxi Milestone Payment For Research And Development Licenses
MilestonePaymentForResearchAndDevelopmentLicenses
1000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2547000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4420000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3132000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8745000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
585000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4325000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-76100000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1264256
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1264256
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1389910
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1389910
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
202000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
143000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
302000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
23000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
168000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
691000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
672000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
857000

Files In Submission

Name View Source Status
0001410578-21-000225-index-headers.html Edgar Link pending
0001410578-21-000225-index.html Edgar Link pending
0001410578-21-000225.txt Edgar Link pending
0001410578-21-000225-xbrl.zip Edgar Link pending
atxi-20210930.xsd Edgar Link pending
atxi-20210930x10q.htm Edgar Link pending
atxi-20210930x10q_htm.xml Edgar Link completed
atxi-20210930xex31d1.htm Edgar Link pending
atxi-20210930xex31d2.htm Edgar Link pending
atxi-20210930xex32d1.htm Edgar Link pending
atxi-20210930xex32d2.htm Edgar Link pending
atxi-20210930_cal.xml Edgar Link unprocessable
atxi-20210930_def.xml Edgar Link unprocessable
atxi-20210930_lab.xml Edgar Link unprocessable
atxi-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending